Parathyroid Hormone Market Size, Share, Industry, Forecast and outlook (2024-2031)

Parathyroid Hormone Market is Segmented By Product Type (Recombinant Parathyroid  Hormone, Natpara, Parathyroid Hormone Analogues, Forteo, Tymlos), By Application (Hypoparathyroidism, Hypocalcemia, Osteoporosis, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Parathyroid Hormone Market

Parathyroid Hormone Market is predicted to grow  at a CAGR 3.4% during the forecast period (2023-2030).

PTH (parathyroid hormone) is a peptide hormone secreted by the parathyroid glands. It binds to bone and kidney receptors. PTH secretion is stimulated by a decrease in serum calcium concentration and an increase in serum phosphorous concentration.

Parathyroid Hormone Market Scope

To Know More Download Sample

Parathyroid Hormone Market Dynamics

The factors influencing the global parathyroid hormone market are the increasing use of parathyroid hormone to regulate and maintain the balance of calcium and phosphorus in the body.

The increasing use of parathyroid hormone for regulating and maintaining the balance of calcium and phosphorus in the body

Parathyroid hormone is used in conjunction with calcium and vitamin D to treat hypocalcemia (low calcium levels in the blood) in people with low parathyroid hormone levels. Thyroid hormone is a human parathyroid hormone (PTH) analog used to treat hypocalcemia caused by hypoparathyroidism. Parathyroid hormone is typically administered after calcium, and vitamin D alone has been ineffective.

For instance, Natpara is a hormone that regulates the parathyroid gland. Parathyroid hormone causes an increase in serum calcium, which causes calcium to enter the circulation. It is specifically indicated in the treatment of hypocalcemia in hypoparathyroidism patients as an adjunct to calcium, and vitamin D. Natpara is only recommended for patients who cannot be well-controlled with calcium supplements and active forms of vitamin D alone due to the risk of osteosarcoma. Natpara is available as a subcutaneous injection solution. Natpara dosage is determined based on total serum calcium (albumin-corrected) and 24-hour urinary calcium excretion.

The side effects associated with parathyroid hormone is expected to hamper the market growth

Side effects of parathyroid hormone include high calcium levels, nausea, vomiting, constipation, increased thirst or urination, muscle weakness, bone pain, confusion, lack of energy, or tired feeling. Some side effects may be serious; for instance, high blood calcium levels symptoms include nausea, vomiting, constipation, fatigue, or muscle weakness. Symptoms of low blood calcium include tingling in the lips, tongue, fingers, and feet, twitching of the face muscles, cramping in the feet and hands, seizures, depression, or difficulties thinking or remembering.

Hence, the side effects of parathyroid hormone are expected to hamper the market.

COVID-19 Impact Analysis On Parathyroid Hormone Market

Covid-19 may affect parathyroid gland function directly through SARS-CoV-2 virus invasion of parathyroid gland tissues and indirectly through respiratory failure and chronic respiratory alkalosis, which can be considered additional mechanisms explaining the prevalence of hypocalcemia in COVID-19 patients. COVID-19 may worsen some medical conditions, such as hypoparathyroidism, under control before the infection. Hypocalcemia, or low calcium levels, has been proposed as an important indicator of COVID-19 severity and appears to be specific to COVID-19 in comparison to other acute respiratory disorders.

Hypocalcemia in COVID-19 patients has been linked to vitamin D deficiency, with a previous study finding a link between vitamin D supplements and a lower risk of COVID-19-related infection and death. Hence, the global parathyroid hormone market is expected to positively impact the forecast period.

Parathyroid Hormone Market Segment Analysis

The recombinant human parathyroid hormone segment is expected to dominate the global parathyroid hormone market

Recombinant human parathyroid hormone, also known as Preotact and Natpara, is a synthetic form of the parathyroid hormone used to treat hypoparathyroidism. In the United States, full-length recombinant human parathyroid hormone is approved as an adjunct to calcium and vitamin D therapy for the treatment of hypocalcaemia in hypoparathyroid patients. There are two recombinant human parathyroid hormones.

For instance, Preotact is a pharmaceutical form of a parathyroid hormone produced by a recombinant DNA-modified strain of Escherichia coli. Preotact is a medication used to treat osteoporosis in postmenopausal women who are at high risk of osteoporotic fractures. There has been a significant reduction in the occurrence of vertebral fractures. Nycomed markets Preotact in Europe. NPS Pharmaceutical, Inc. owns the registered trademark Preos.

Parathyroid Hormone Market Geographical Analysis

North America region is expected to hold the largest market share in the global parathyroid hormone market

The increasing incidence of osteoporosis and hypoparathyroidism is expected to drive the market in this region. For instance, according to the National Osteoporosis Foundation, osteoporosis is a bone disease that causes a person's bones to become weak and brittle. Around 10 million Americans have osteoporosis, and another 44 million have low bone density, putting them at risk. 54 million Americans, or half of all adults over 50, are at risk of breaking a bone. In postmenopausal osteoporosis and glucocorticoid-induced osteoporosis, the parathyroid hormone reduces vertebral fractures and increases spinal bone density, but at the expense of a decrease in radius bone density.

Moreover, hypoparathyroidism, a rare calcium-depleting disease, affects approximately 70,000 people in the United States. Hence, with the increasing incidence of both diseases, the demand for parathyroid hormone is expected to grow. For instance, in 2015, the US Food and Drug Administration (FDA) approved Natpara, a once-daily subcutaneous injectable recombinant parathyroid hormone (PTH) product, as an adjunct to calcium and vitamin D to control hypocalcemia in hypoparathyroid patients.

Parathyroid Hormone Market Competitive Landscape

The global parathyroid hormone market is moderately competitive with product launches, mergers, and acquisitions. Some of the key players in the market are Eli Lilly and Company, Radius Health, Inc, Ascendis Pharma, Takeda Pharmaceutical Company Limited, Alvogen Inc.

Takeda Pharmaceutical Company Limited

Overview: Takeda Pharmaceutical Company Limited is a multinational pharmaceutical company based in Japan. The company was founded in 1781. Takeda concentrates its research and development efforts in four therapeutic areas oncology, rare genetic and hematology, neuroscience, and gastroenterology (GI).

Product Portfolio: The company’s NATPARA (parathyroid hormone) for Injection is a parathyroid hormone used in conjunction with calcium and vitamin D to control hypocalcemia in hypoparathyroid patients.